Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01265264 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol
A Phase 2 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 279
- Enrollment target
NCT01265264 is a Phase 2 study that has completed, run by BioCryst Pharmaceuticals. The registered enrollment target is 279 participants.
The verdict
NCT01265264, a Phase 2 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 279 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether ulodesine and allopurinol combined for 12 weeks are effective in treating gout in patients who are not adequately responding to allopurinol alone.
Interventions
- DRUG Placebo
- DRUG ulodesine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01265264
The ClinicalTrials.gov registry entry for NCT01265264 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 279 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01265264 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01265264 about?
NCT01265264 is a clinical study titled "Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol". The purpose of this study is to determine whether ulodesine and allopurinol combined for 12 weeks are effective in treating gout in patients who are not adequately responding to allopurinol alone.
What is the current status of trial NCT01265264?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 279 participants. The study started on 2010-12. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01265264?
The interventions under investigation include: Placebo (DRUG), ulodesine (DRUG).
Who is sponsoring clinical trial NCT01265264?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.